Login Register Cart 0
Generic placeholder image

Current Protein & Peptide Science

Editor-in-Chief

ISSN (Print): 1389-2037
ISSN (Online): 1875-5550

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer

Author(s): Drashti Desai and Pravin Shende*

Volume 21, Issue 11, 2020

Page: [1097 - 1102] Pages: 6

DOI: 10.2174/1389203721666200918151604

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

Immunotherapy emerges as a treatment strategy for breast cancer marker, diagnosis and treatment. In this review, monoclonal antibodies (mAbs)-based passive and peptide vaccines as active immunotherapy approaches like activation of B-cells and T-cells are studied. Passive immunotherapy is mAbs-based therapy effective against tumor cells, which acts by targeting HER2, IGF 1R, VEGF, BCSC and immune checkpoints. Neuropeptide Y (NPY) and GPCR are the areas of interest to target BC metastases for on-targeting therapeutic action. Neuropeptide S (NPS) or NPS receptor 1, acts as a biomarker for Neuroendocrine tumors (NET), mostly characterized by synaptophysin and chromogranin-A expression or Ki-67 proliferation index. The protein fusion technologies arise as a promising avenue in plant expression systems for increased recombinant Ab accumulation and cost-efficient purification. Recently, mAbs-based immunotherapy effectiveness is appreciated as a novel therapeutic combination of chemotherapy and immunotherapy to reduce the side effects and improve therapeutic responsiveness. Synthetic drug resistance will be overcome by mAbs-based therapy through several clinical trials and detection methods need to be optimized for accuracy and precision. Pharmacokinetic attributes need to be accessed for preferred receptor-agonist activity without ligand accumulation.

Keywords: Antigen, receptor, immunity, immunotherapy, antibody, breast cancer.

« Previous Next »
Graphical Abstract

[1]
Liu, L.; Xu, Q.; Cheng, L.; Ma, C.; Xiao, L.; Xu, D.; Gao, Y.; Wang, J.; Song, H. NPY1R is a novel peripheral blood marker predictive of metastasis and prognosis in breast cancer patients. Oncol. Lett., 2015, 9(2), 891-896.
[http://dx.doi.org/10.3892/ol.2014.2721] [PMID: 25624911]
[2]
Morgat, C.; Mishra, A.K.; Varshney, R.; Allard, M.; Fernandez, P.; Hindié, E. Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J. Nucl. Med., 2014, 55(10), 1650-1657.
[http://dx.doi.org/10.2967/jnumed.114.142000] [PMID: 25189338]
[3]
Shende, P.; Desai, D. Physiological and therapeutic roles of neuropeptide Y on biological functions. Adv. Exp. Med. Biol., 2020, 1237, 37-47.
[http://dx.doi.org/10.1007/5584_2019_427] [PMID: 31468359]
[4]
Santos-Carvalho, A.; Ambrósio, A.F.; Cavadas, C. Neuropeptide Y system in the retina: From localization to function. Prog. Retin. Eye Res., 2015, 47, 19-37.
[http://dx.doi.org/10.1016/j.preteyeres.2015.03.001] [PMID: 25797468]
[5]
Farzi, A.; Reichmann, F.; Holzer, P. The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour. Acta Physiol. (Oxf.), 2015, 213(3), 603-627.
[http://dx.doi.org/10.1111/apha.12445] [PMID: 25545642]
[6]
Reichmann, F.; Holzer, P.; Neuropeptide, Y. Neuropeptide Y: A stressful review. Neuropeptides, 2016, 55, 99-109.
[http://dx.doi.org/10.1016/j.npep.2015.09.008] [PMID: 26441327]
[7]
Li, J.; Tian, Y.; Wu, A. Neuropeptide Y receptors: a promising target for cancer imaging and therapy. Regen. Biomater., 2015, 2(3), 215-219.
[http://dx.doi.org/10.1093/rb/rbv013] [PMID: 26816643]
[8]
Reubi, J.C.; Gugger, M.; Waser, B.; Schaer, J.C. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res., 2001, 61(11), 4636-4641.
[PMID: 11389101]
[9]
Ruscica, M.; Dozio, E.; Motta, M.; Magni, P. Relevance of the neuropeptide Y system in the biology of cancer progression. Curr. Top. Med. Chem., 2007, 7(17), 1682-1691.
[http://dx.doi.org/10.2174/156802607782341019] [PMID: 17979777]
[10]
Pedrazzini, T.; Pralong, F.; Grouzmann, E. Neuropeptide Y: the universal soldier. Cell. Mol. Life Sci., 2003, 60(2), 350-377.
[http://dx.doi.org/10.1007/s000180300029] [PMID: 12678499]
[11]
Mullins, D.E.; Zhang, X.; Hawes, B.E. Activation of extracellular signal regulated protein kinase by neuropeptide Y and pancreatic polypeptide in CHO cells expressing the NPY Y(1), Y(2), Y(4) and Y(5) receptor subtypes. Regul. Pept., 2002, 105(1), 65-73.
[http://dx.doi.org/10.1016/S0167-0115(01)00388-3] [PMID: 11853873]
[12]
Memminger, M.; Keller, M.; Lopuch, M.; Pop, N.; Bernhardt, G.; von Angerer, E.; Buschauer, A. The neuropeptide y y(1) receptor: a diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts. PLoS One, 2012, 7(12)e51032
[http://dx.doi.org/10.1371/journal.pone.0051032] [PMID: 23236424]
[13]
Amlal, H.; Faroqui, S.; Balasubramaniam, A.; Sheriff, S. Estrogen up-regulates neuropeptide Y Y1 receptor expression in a human breast cancer cell line. Cancer Res., 2006, 66(7), 3706-3714.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-2744] [PMID: 16585197]
[14]
Zhang, L.; Bijker, M.S.; Herzog, H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol. Ther., 2011, 131(1), 91-113.
[http://dx.doi.org/10.1016/j.pharmthera.2011.03.011] [PMID: 21439311]
[15]
Sheriff, S.; Ali, M.; Yahya, A.; Haider, K.H.; Balasubramaniam, A.; Amlal, H. Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line. Mol. Cancer Res., 2010, 8(4), 604-614.
[http://dx.doi.org/10.1158/1541-7786.MCR-09-0301] [PMID: 20332211]
[16]
Yi, M.; Li, H.; Wu, Z.; Yan, J.; Liu, Q.; Ou, C.; Chen, M. A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in Humans. Cell. Physiol. Biochem., 2018, 45(1), 88-107.
[http://dx.doi.org/10.1159/000486225] [PMID: 29310113]
[17]
Tilan, J.; Kitlinska, J.; Neuropeptide, Y. Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology. Neuropeptides, 2016, 55, 55-66.
[http://dx.doi.org/10.1016/j.npep.2015.10.005] [PMID: 26549645]
[18]
Langer, M.; Kratz, F.; Rothen-Rutishauser, B.; Wunderli-Allenspach, H.; Beck-Sickinger, A.G. Novel peptide conjugates for tumor-specific chemotherapy. J. Med. Chem., 2001, 44(9), 1341-1348.
[http://dx.doi.org/10.1021/jm001065f] [PMID: 11311056]
[19]
Sanada, K.; Alda Díez, M.; Salas Valero, M.; Pérez-Yus, M.C.; Demarzo, M.M.P.; Montero-Marín, J.; García-Toro, M.; García-Campayo, J. Effects of mindfulness-based interventions on biomarkers in healthy and cancer populations: a systematic review. BMC Complement. Altern. Med., 2017, 17(1), 125.
[http://dx.doi.org/10.1186/s12906-017-1638-y] [PMID: 28231775]
[20]
Carvalho, L.S.; da Silva, O.B.; de Almeida, G.C.; de Oliveira, J.D.; Parachin, N.S.; Carmo, T.S. Production Processes for Monoclonal Antibodies; Fermentation Processes, 2017, pp. 182-198.
[21]
Moussavou, G.; Ko, K.; Lee, J.H.; Choo, Y.K. Production of monoclonal antibodies in plants for cancer immunotherapy. BioMed Res. Int., 2015, 2015306164
[http://dx.doi.org/10.1155/2015/306164] [PMID: 26550566]
[22]
Strome, S.E.; Sausville, E.A.; Mann, D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist, 2007, 12(9), 1084-1095.
[http://dx.doi.org/10.1634/theoncologist.12-9-1084] [PMID: 17914078]
[23]
Bernard-Marty, C.; Lebrun, F.; Awada, A.; Piccart, M.J. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs, 2006, 66(12), 1577-1591.
[http://dx.doi.org/10.2165/00003495-200666120-00004] [PMID: 16956305]
[24]
Mohit, E.; Hashemi, A.; Allahyari, M. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert Rev. Clin. Immunol., 2014, 10(7), 927-961.
[http://dx.doi.org/10.1586/1744666X.2014.916211] [PMID: 24867051]
[25]
Pento, J.T. Monoclonal Antibodies for the Treatment of Cancer. Anticancer Res., 2017, 37(11), 5935-5939.
[PMID: 29061772]
[26]
Awwad, S.; Angkawinitwong, U. Overview of antibody drug delivery. Pharmaceutics, 2018, 10(3), 83.
[http://dx.doi.org/10.3390/pharmaceutics10030083] [PMID: 29973504]
[27]
Shende, P.K.; Desai, D.; Gaud, R.S. Role of solid-gas interface of nanobubbles for therapeutic applications. Crit. Rev. Ther. Drug Carrier Syst., 2018, 35(5), 469-494.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2018020229] [PMID: 30317946]
[28]
Desai, D.; Shende, P. Drug-Free Cyclodextrin-Based Nanosponges for Antimicrobial Activity. J. Pharm. Innov., 2020, 1-11.
[29]
Deng, Y.J.; Andrews, G.C.; Karush, F. Epitopic characterization of neuropeptide Y (NPY) by alanine-scanning mutagenesis. Hybridoma, 1996, 15(2), 159-162.
[http://dx.doi.org/10.1089/hyb.1996.15.159] [PMID: 8743297]
[30]
Kitlinska, J.; Abe, K.; Kuo, L.; Pons, J.; Yu, M.; Li, L.; Tilan, J.; Everhart, L.; Lee, E.W.; Zukowska, Z.; Toretsky, J.A. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res., 2005, 65(5), 1719-1728.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-2192] [PMID: 15753367]
[31]
Prewett, M.; Huber, J.; Li, Y.; Santiago, A.; O’Connor, W.; King, K.; Overholser, J.; Hooper, A.; Pytowski, B.; Witte, L.; Bohlen, P.; Hicklin, D.J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res., 1999, 59(20), 5209-5218.
[PMID: 10537299]
[32]
Medeiros, P.J.; Al-Khazraji, B.K.; Novielli, N.M.; Postovit, L.M.; Chambers, A.F.; Jackson, D.N. Neuropeptide Y stimulates proliferation and migration in the 4T1 breast cancer cell line. Int. J. Cancer, 2012, 131(2), 276-286.
[http://dx.doi.org/10.1002/ijc.26350] [PMID: 21823118]
[33]
Garvan Institute of Medical Research PCT/AU2012/001464.
[34]
Pulkkinen, V.; Ezer, S.; Sundman, L.; Hagström, J.; Remes, S.; Söderhäll, C.; Greco, D.; Haglund, C.; Kere, J.; Arola, J. Neuropeptide S receptor 1 (NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors. Virchows Arch., 2014, 465(2), 173-183.
[http://dx.doi.org/10.1007/s00428-014-1602-x] [PMID: 24915894]
[35]
Körner, M.; Reubi, J.C. NPY receptors in human cancer: a review of current knowledge. Peptides, 2007, 28(2), 419-425.
[http://dx.doi.org/10.1016/j.peptides.2006.08.037] [PMID: 17223228]

Rights & Permissions Print Cite
Article Metrics
40
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy